On binding to its target hormone, the oestrogen-receptor protein modulates the expression of many genes. Changes in the receptor's interaction with DNA have now been linked to clinical outcome in patients with breast cancer. See Letter p.389
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Ross-Innes, C. S. et al. Nature 481, 389–393 (2012).
Lupien, M. & Brown, M. Endocr.-Relat. Cancer 16, 381–389 (2009).
Carroll, J. S. et al. Cell 122, 33–43 (2005).
Laganière, J. et al. Proc. Natl Acad. Sci. USA 102, 11651–11656 (2005).
Zaret, K. S. & Carroll, J. S. Genes Dev. 25, 2227–2241 (2011).
Hurtado, A., Holmes, K. A., Ross-Innes, C. S., Schmidt, D. & Carroll, J. S. Nature Genet. 43, 27–33 (2011).
Lupien, M. et al. Genes Dev. 24, 2219–2227 (2010).
Biddie, S. C. et al. Mol. Cell 43, 145–155 (2011).
Robinson, J. L. et al. EMBO J. 30, 3019–3027 (2011).
Ni, M. et al. Cancer Cell 20, 119–131 (2011).
Deblois, G. et al. Cancer Res. 69, 6149–6157 (2009).
Xu, J., Wu, R. C. & O'Malley, B. W. Nature Rev. Cancer 9, 615–630 (2009).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Deblois, G., Giguère, V. Reprogramming clinical outcome. Nature 481, 275–276 (2012). https://doi.org/10.1038/481275a
Published:
Issue Date:
DOI: https://doi.org/10.1038/481275a
